US Patent No: 5,475,092

Number of patents in Portfolio can not be more than 2000

Cell binding agent conjugates of analogues and derivatives of CC-1065

2 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Novel cytotoxic agents comprising a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOGEN, INC.WALTHAM, MA90

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blattler, Walter A Brookline, MA 30 587
Chari, Ravi V J Newton, MA 66 405
Goldmakher, Viktor S Newton, MA 17 152

Cited Art

Patent Info (Count) # Cites Year
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,045,451 Methods for screening antibodies for use as immunotoxins 72 1988
 
Bristol-Myers Company (1)
4,301,248 Fermentation process for making rachelmycin 5 1980
 
CHECKFREE SERVICES CORPORATION (1)
7,809,639 System and method to provide interoperable service across multiple clients 3 2002
 
NEORX CORPORATION (1)
5,106,951 Antibody conjugates 59 1989
 
The Upjohn Company (1)
4,912,227 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds 34 1986

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
IMMUNOGEN, INC. (28)
6,340,701 Cytotoxic agents comprising taxanes and their therapeutic use 29 2000
6,372,738 Cytotoxic agents comprising taxanes and their therapeutic use 13 2001
6,436,931 Cytotoxic agents comprising taxanes and their therapeutic use 21 2002
6,756,397 Prodrugs of CC-1065 analogs 13 2002
6,706,708 Cytotoxic agents comprising taxanes and their therapeutic use 3 2002
7,390,898 Cytotoxic agents containing novel potent taxanes and their therapeutic use 0 2003
7,008,942 Cytotoxic agents comprising taxanes and their therapeutic use 0 2003
7,049,316 Prodrugs of CC-1065 analogs 5 2003
7,374,762 Drug conjugate composition 3 2004
7,495,114 Cytotoxic agents containing novel potent taxanes and their therapeutic use 0 2004
7,414,073 Cytotoxic agents containing novel potent taxanes and their therapeutic use 0 2004
7,217,819 Cytotoxic agents comprising taxanes and their therapeutic use 0 2005
7,388,026 Prodrugs of CC-1065 analogs 2 2005
7,528,130 Cytotoxic agents comprising taxanes and their therapeutic use 0 2006
7,276,499 Cytotoxic agents comprising taxanes and their therapeutic use 0 2006
7,811,572 Process for preparing purified drug conjugates 0 2006
7,514,080 Drug conjugate composition 3 2006
7,501,120 Drug conjugate composition 2 2006
7,494,649 Drug conjugate composition 2 2006
7,655,660 Prodrugs of CC-1065 analogs 2 2007
7,550,609 Cytotoxic agents comprising taxanes and their therapeutic use 0 2007
7,476,669 Cytotoxic agents comprising taxanes and their therapeutic use 0 2007
7,585,857 Cytotoxic agents comprising taxanes and their therapeutic use 0 2007
7,655,661 Prodrugs of CC-1065 analogs 2 2008
8,012,978 Prodrugs of CC-A1065 analogs 0 2008
8,012,485 Drug conjugate composition 1 2009
7,906,545 Prodrugs of CC-1065 analogs 0 2009
8,383,122 Process for preparing purified drug conjugates 0 2010
 
MEDAREX, INC. (16)
7,129,261 Cytotoxic agents 22 2002
7,087,600 Peptidyl prodrugs and linkers and stabilizers useful therefor 18 2002
6,989,452 Disulfide prodrugs and linkers and stabilizers useful therefor 15 2002
7,691,962 Chemical linkers and conjugates thereof 6 2005
7,517,903 Cytotoxic compounds and conjugates 8 2005
7,498,302 Disulfide prodrugs and linkers and stabilizers useful therefor 0 2005
7,507,420 Peptidyl prodrugs and linkers and stabilizers useful therefor 12 2005
7,714,016 Cytotoxic compounds and conjugates with cleavable substrates 5 2006
8,124,738 Human monoclonal antibodies to CD70 0 2006
7,847,105 Methods and compounds for preparing CC-1065 analogs 0 2006
7,968,586 Cytotoxic compounds and conjugates 0 2006
8,461,117 Chemical linkers and cleavable substrates and conjugates thereof 0 2007
RE41252 Peptidyl prodrugs and linkers and stabilizers useful therefor 0 2008
8,034,959 Methods of treating cancer with an antibody-drug conjugate 0 2009
7,977,465 Peptidyl prodrugs and linkers and stabilizers useful therefor 0 2009
8,399,403 Chemical linkers and conjugates thereof 0 2009
 
SANOFI (4)
8,460,667 EPHA2 receptor antagonist antibodies 0 2007
8,153,765 Anti-CD38 antibodies for the treatment of cancer 0 2007
8,388,965 Antibodies that bind IL-4 and/or IL-13 and their uses 0 2008
8,404,678 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use 0 2010
 
ALCHEMIA ONCOLOGY PTY LIMITED (2)
8,287,894 Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease 0 2005
8,388,993 Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer 0 2006
 
The Scripps Research Institute (2)
6,262,271 ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins 15 2000
6,486,326 iso-CBI and iso-CI analogs of CC-1065 duocarmycins 15 2001
 
BAYLOR COLLEGE OF MEDICINE (1)
5,780,446 Formulations of vesicant drugs and methods of use thereof 13 1996
 
COMPUGEN LTD. (1)
7,745,391 Human thrombospondin polypeptide 9 2006
 
JCRT Radiation Oncology Support Services, Inc. (1)
6,368,598 Drug complex for treatment of metastatic prostate cancer 11 1998
 
PROLX PHARMACEUTICALS CORP. (1)
6,552,060 Asymmetric disulfides and methods of using same 3 1998